- Trials with a EudraCT protocol (252)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
252 result(s) found for: Regulatory T cells.
Displaying page 1 of 13.
EudraCT Number: 2014-005174-11 | Sponsor Protocol Number: U1111-1166-6923 | Start Date*: 2015-10-01 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: A randomized, double-blinded placebo-controlled, paralleled designed, investigator sponsored study of the effect of the GLP-1 receptor agonist liraglutide on beta-cell function in C-peptide positiv... | ||
Medical condition: Beta-cell function in C-peptide positive type 1 diabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-007792-24 | Sponsor Protocol Number: 1.1 | Start Date*: 2009-03-13 |
Sponsor Name:Medical University of Graz, Department of Internal Medicine, Div. Endocrinology and Nuclear Medicine | ||
Full Title: Effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters | ||
Medical condition: Healthy volunteers. The intended indication for the product under development is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension) metabolic ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000914-12 | Sponsor Protocol Number: GASOLINE | Start Date*: 2020-06-12 | ||||||||||||||||||||||||||
Sponsor Name:University of Cologne | ||||||||||||||||||||||||||||
Full Title: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors | ||||||||||||||||||||||||||||
Medical condition: • Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor) • Prostate carcino... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018901-12 | Sponsor Protocol Number: ADPP-002ENM-DA-017 | Start Date*: 2010-10-20 |
Sponsor Name:Medical University Graz, Department of Internal Medicine, Div. Endocrinology and Metabolism [...] | ||
Full Title: Placebo controlled study on effects of vitamin D supplementation in type 1 diabetic subjects on immunological, endocrine and metabolic parameters: Step 2 of the Austrian Diabetes Prevention Program... | ||
Medical condition: To evaluate whether vitamin D supplementation in type 1 diabetic subjects significantly alters the proportion of regulatory T-cells of all circulating CD4 positive T-cells. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004324-14 | Sponsor Protocol Number: WU-CART-007-1001 | Start Date*: 2023-06-26 | ||||||||||||||||
Sponsor Name:Wugen, Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic L... | ||||||||||||||||||
Medical condition: Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015523-91 | Sponsor Protocol Number: ENM-EA-011 | Start Date*: 2010-01-21 |
Sponsor Name:Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin | ||
Full Title: Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters | ||
Medical condition: healthy volunteers. The intended indication for the investigated product is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension), metabolic (e.g... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003947-12 | Sponsor Protocol Number: Treg003 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Freistaat Bayern represented by University of Regensburg represented by Kaufmännischer Direktor | |||||||||||||
Full Title: Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells | |||||||||||||
Medical condition: Treatment of steroid-resistant chronic graft-versus-host disease with donor-derived regulatory T cells | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001696-36 | Sponsor Protocol Number: IL2REG | Start Date*: 2019-10-09 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: Study of efficacy of low-dose recombinant human interleukin-2 in immunological changes associated with depression (IL2REG) | |||||||||||||
Medical condition: Depressive episode in course of mood disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003910-26 | Sponsor Protocol Number: 01/2015 | Start Date*: 2017-12-11 |
Sponsor Name:Núcleo de Estudos de Hipertensão da Beira Interior | ||
Full Title: Fase II, unicenter, open, randomized trial to evaluate the response of Th17 and T regulatory lymphocytes to 24 weeks supplementation with cholecalciferol in patients with arterial hypertension, obe... | ||
Medical condition: Obesity associated arterial hypertension Metabolic syndrome associated arterial hypertension | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: PT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004566-17 | Sponsor Protocol Number: EORTC-1820-CLTF | Start Date*: 2021-07-22 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Cutaneous T-cell lymphoma (Mycosis Fungoides (MF) and Sézary Syndrome (SS)) | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005713-39 | Sponsor Protocol Number: 42970 | Start Date*: 2014-09-02 |
Sponsor Name:St. Antonius Hospital | ||
Full Title: Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) | ||
Medical condition: multiple myeloma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001927-74 | Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) | Start Date*: 2009-01-16 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES... | ||
Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005210-22 | Sponsor Protocol Number: BOOG-2017-02 | Start Date*: 2018-04-25 | |||||||||||
Sponsor Name:BOOG Study Center | |||||||||||||
Full Title: Explorative trial to identify the impact of denosumab on the systemic immunity and local immunologic microenvironment in postmenopausal patients with HER2 negative breast cancer. | |||||||||||||
Medical condition: Mamma carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003643-10 | Sponsor Protocol Number: NAM | Start Date*: Information not available in EudraCT |
Sponsor Name:UMC Utrecht | ||
Full Title: Modulating regulatory T cell function in JIA with Vitamin B3 (nicotinamide) treatment | ||
Medical condition: Juvenile idiopathic arthritis (JIA) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003384-30 | Sponsor Protocol Number: IR902-231 | Start Date*: 2007-02-26 |
Sponsor Name:The Immune Response Corporation | ||
Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis | ||
Medical condition: Multiple Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001515-20 | Sponsor Protocol Number: 12971/16 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI | |||||||||||||
Full Title: EFFECT OF TERIFLUNOMIDE ON T CELL SUBPOPULATIONS IN PERIPHERAL BLOOD FROM RRMS PATIENTS | |||||||||||||
Medical condition: RELAPSING-REMITTING MULTIPLE SCLEROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002685-12 | Sponsor Protocol Number: Treg002 | Start Date*: 2013-05-22 | |||||||||||
Sponsor Name:University Hospital Regensburg | |||||||||||||
Full Title: Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells A prospective open-label one-armed non-randomized mul... | |||||||||||||
Medical condition: Steroid resistant severe acute gastrointestinal graft-versus-host disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001080-27 | Sponsor Protocol Number: CD45RADLIHaplo | Start Date*: 2022-11-23 | |||||||||||
Sponsor Name:University Hospital Tuebingen | |||||||||||||
Full Title: A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic... | |||||||||||||
Medical condition: Patients suffering from hematological malignancies and eligible for haploidentical allogeneic stem cell transplantation. Patients will be included prior start of conditioning for SCT. Inclusion cri... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004144-22 | Sponsor Protocol Number: BORLEUWT01 | Start Date*: 2012-01-12 |
Sponsor Name:Institut Jules Bordet - Université Libre de Bruxelles | ||
Full Title: A Phase I/II study to assess the safety and immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) combined with infusions of ex vivo regulatory T cells depleted T lymph... | ||
Medical condition: For adult patients with WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for high risk patients) or in CR2 or CR3 who are not eligible for allogeneic stem cell transplantation (SCT) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
